BRPI0606943A2 - fornecimento no cólon de agentes ativos - Google Patents

fornecimento no cólon de agentes ativos

Info

Publication number
BRPI0606943A2
BRPI0606943A2 BRPI0606943-6A BRPI0606943A BRPI0606943A2 BR PI0606943 A2 BRPI0606943 A2 BR PI0606943A2 BR PI0606943 A BRPI0606943 A BR PI0606943A BR PI0606943 A2 BRPI0606943 A2 BR PI0606943A2
Authority
BR
Brazil
Prior art keywords
colon
release
polyethyleneimine
amount
pectin beads
Prior art date
Application number
BRPI0606943-6A
Other languages
English (en)
Inventor
Elias Fattal
Antoine Andremont
Patrick Couvreur
Sandrine Bourgeois
Original Assignee
Da Volterra
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra, Centre Nat Rech Scient filed Critical Da Volterra
Publication of BRPI0606943A2 publication Critical patent/BRPI0606943A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FORNECIMENTO NO CóLON DE AGENTES ATIVOS. A presente invenção refere-se a dispositivos para o fornecimento de fármacos que são administrados oralmente e que liberam ingredientes ativos no cólon. Em uma modalidade, os ingredientes ativos são aqueles que inativam antibióticos, tais como macrolidas, quinolonas e antibióticos que contêm beta-lactam. Um exemplo de um agente ativo adequado é uma enzima tal como as beta-lactamases. Em uma outra modalidade, os agentes ativos são aqueles que tratam especificamente distúrbios do cólon, tais como Doença de Chrohn, síndrome do intestino irritável, colite ulcerativa, câncer colorretal ou constipação. Os dispositivos de fornecimento de fármacos estão na forma de esferas de pectina, reticuladas com cálcio e reticuladas com polietilenoimina. Acredita-se que a alta densidade da reticulação da polietilenoimina estabiliza as esferas de pectina durante uma quantidade de tempo suficiente de forma que uma quantidade substancial dos ingredientes ativos pode ser administrada diretamente no cólon. Vantajosamente, a quantidade de polietilenoimina é suficiente para permitir que uma parte substancial das esferas de pectina passe através do trato gastrointestinal até o cólon sem a liberação do agente ativo e é ainda suficiente de forma que as esferas de pectina são suficientemente degradadas no cólon para liberar uma quantidade eficaz do agente ativo.
BRPI0606943-6A 2005-02-09 2006-02-09 fornecimento no cólon de agentes ativos BRPI0606943A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65134205P 2005-02-09 2005-02-09
PCT/GB2006/000448 WO2006085075A2 (en) 2005-02-09 2006-02-09 Colonic delivery of active agents

Publications (1)

Publication Number Publication Date
BRPI0606943A2 true BRPI0606943A2 (pt) 2009-07-28

Family

ID=36793399

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606943-6A BRPI0606943A2 (pt) 2005-02-09 2006-02-09 fornecimento no cólon de agentes ativos

Country Status (8)

Country Link
US (1) US20080317666A1 (pt)
EP (1) EP1845948A2 (pt)
JP (1) JP2008529996A (pt)
CN (1) CN101128187A (pt)
AU (1) AU2006211996A1 (pt)
BR (1) BRPI0606943A2 (pt)
CA (1) CA2595526A1 (pt)
WO (1) WO2006085075A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
MY157759A (en) 2006-11-28 2016-07-15 Univ Namur Composition comprising oligogalacturonans and polycationic saccharides
RU2010113965A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства
JP2010539027A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
WO2009046852A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
JP5504666B2 (ja) * 2009-03-25 2014-05-28 ニプロ株式会社 医薬組成物、その製造方法及び徐放性基材
PH12012500521A1 (en) 2009-11-19 2024-02-12 Taigen Biotechnology Co Ltd Hcv protease inhibitors
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
CN108289894A (zh) 2015-09-29 2018-07-17 前药扩展私人有限公司 新型制剂和治疗方法
US10940113B2 (en) * 2017-02-24 2021-03-09 Medical And Pharmaceutical Industry Technology And Development Center Pharmaceutical composition for colon targeting, method for treating a colon-related disease using the same and preparation method thereof
EP3829637A1 (en) * 2018-08-05 2021-06-09 Da Volterra Method for improving anticancer agent efficacy
AU2019320825B2 (en) * 2018-08-17 2025-09-25 Cepheid Methods and compositions for nucleic acid isolation
CN113730374B (zh) * 2021-08-05 2023-03-24 中新国际联合研究院 一种甜菜果胶基口服缓释凝胶珠及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
FR2608456B1 (fr) * 1986-12-18 1993-06-18 Mero Rousselot Satia Microcapsules a base de gelatine et de polysaccharides et leur procede d'obtention
EP0454044B1 (de) * 1990-04-25 1995-12-06 Hoechst Aktiengesellschaft Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff
FI920206A0 (fi) * 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
EP1369043B1 (en) * 1996-10-09 2010-05-26 Givaudan SA Use of beads as food additives
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
IL130303A0 (en) * 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
FR2843301B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
WO2006085075A2 (en) 2006-08-17
WO2006085075A3 (en) 2007-08-30
US20080317666A1 (en) 2008-12-25
AU2006211996A1 (en) 2006-08-17
CN101128187A (zh) 2008-02-20
JP2008529996A (ja) 2008-08-07
CA2595526A1 (en) 2006-08-17
EP1845948A2 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
BRPI0606943A2 (pt) fornecimento no cólon de agentes ativos
Higuchi et al. Oral recombinant methioninase combined with caffeine and doxorubicin induced regression of a doxorubicin-resistant synovial sarcoma in a PDOX mouse model
Falagas et al. Fosfomycin
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BR0211781A (pt) Forma de dosagem oral, e, métodos para tratar ou prevenir dor, e para preparar forma de dosagem oral
BRPI0708640A8 (pt) composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
Abdul-Mutakabbir et al. Teaching an old class new tricks: a novel semi-synthetic aminoglycoside, plazomicin
JP2006526644A5 (pt)
BR9901782A (pt) Forma para dosagem de nefazodona.
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BRPI0406484A (pt) Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
CA2304948A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
Agarwal et al. Evaluation of capsaicin ointment at the Korean hand acupressure point K‐D2 for prevention of postoperative nausea and vomiting
ATE206043T1 (de) Örtliche arzneistoffabgabe in tieferen magendarmtraktabschnitten
Sierra et al. Ethanol lock for prevention of CVC-related bloodstream infection in pediatric patients: a systematic review and meta-analysis
BRPI0510226A (pt) composição farmacêutica sólida, forma de dosagem sólida, método para administrar heparina a um animal, método para tratar ou evitar trombose em um animal, método para preparar uma forma de dosagem sólida de heparina umidecida
NO20020829L (no) Ny anvendelse av docetaxel for behandling av hepatoma
BR0114276A (pt) Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]